Variations in Pain Prevalence, Severity, and Analgesic Use by Duration of Survivorship: a Cross-sectional Study of 505 Post-treatment Head and Neck Cancer Survivors

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2021 Dec 7

PMID 34872526

Citations 9

Authors

Jenny L Ren

Raniv D Rojo

Joy Vanessa D Perez

Sai-Ching J Yeung

Ehab Y Hanna

Cielito C Reyes-Gibby

Affiliations

Soon will be listed here.

Abstract

Background: Studies suggest a high prevalence of pain in head and neck cancer (HNC) patients at diagnosis, during and after treatment; however, these studies had small sample sizes and did not comprehensively assess factors known to influence pain. We surveyed a large cohort of HNC survivors to determine variations in the prevalence of pain, its treatment and management by duration of survivorship, and assessed a comprehensive list of risk factors.

Methods: A cross sectional survey of post-treatment survivors of HNC during routine follow-up clinic visits.

Results: A total of 505 HNC survivors with a median follow up of 3 years from cancer diagnosis were included in the study. Overall, 45% (n = 224) reported pain and 14.5, 22 and 7% reported use of prescribed pain medication, over-the-counter pain medication and alternative pain therapies, respectively. Prevalence of severe pain was 7.3% and did not vary significantly by years of survivorship (< 1 year = 5.7%; 1 to < 3 years = 7.1%; 3 to < 8 years = 7.6%; 8 years or more =9.7%; P = 0.392). However, use of prescribed pain medication significantly varied by years of survivorship (< 1 year = 45.7%; 1 to < 3 years = 24.6%; 3 to < 8 years = 18.9; 8 years or more = 18.3%; p < 0.001). Of note, a significant proportion of survivors reported moderate to severe pain (moderate to severe = 55.7% versus none to mild = 44.3%) despite step 3 analgesic use (p < 0.001). Multivariable regression shows that recurrent disease (OR 6.77, 95% CI [1.44, 31.80]), history of chemotherapy (OR 6.00, 95% CI [2.10, 17.14]), and depression (Mild-moderate OR 5.30, 95% CI [2.20, 12.78]; Major OR 8.00, 95% CI [2.67, 23.96]) were significant risk factors for severe pain.

Conclusions: We identified a high prevalence of pain among HNC survivors and determined that analgesic use varied by the duration of survivorship. Therefore, routine surveillance for pain must be consistent throughout the course of survivorship.

Citing Articles

Diet Quality and Dietary Intake in Breast Cancer Survivors Suffering from Chronic Pain: An Explorative Case-Control Study.

Yilmaz S, Elma O, Nijs J, Clarys P, Coppieters I, Deliens T Nutrients. 2024; 16(22).

PMID: 39599630 PMC: 11597644. DOI: 10.3390/nu16223844.

The effects of opioid tapering on select endocrine measures in men and women with head and neck cancer-a longitudinal 12-month study.

Kallman T, Backryd E Pain Rep. 2024; 9(5):e1183.

PMID: 39285953 PMC: 11404959. DOI: 10.1097/PR9.0000000000001183.

Prevalence of pain in a sample of long-term survivors of head and neck cancer.

Howren M, Christensen A, Pagedar N Am J Otolaryngol. 2024; 45(4):104300.

PMID: 38640810 PMC: 11168893. DOI: 10.1016/j.amjoto.2024.104300.

Technical guideline for intra-prepontine cisternal drug delivery via spinal puncture through subarachnoid catheterization.

Li X, Wang Y, Zou D, Zhang W, Li X, He P Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024; 49(1):1-10.

PMID: 38615160 PMC: 11017027. DOI: 10.11817/j.issn.1672-7347.2024.230597.

Bolnykh I, Patterson J, Harding S, Watson L, Lu L, Hurley K J Cancer Surviv. 2024; .

PMID: 38421499 DOI: 10.1007/s11764-024-01554-x.

References

Haisfield-Wolfe M, McGuire D, Soeken K, Geiger-Brown J, De Forge B . Prevalence and correlates of depression among patients with head and neck cancer: a systematic review of implications for research. Oncol Nurs Forum. 2009; 36(3):E107-25. DOI: 10.1188/09.ONF.E107-E125. View

Lalla R, Brennan M, Gordon S, Sonis S, Rosenthal D, Keefe D . Oral Mucositis Due to High-Dose Chemotherapy and/or Head and Neck Radiation Therapy. J Natl Cancer Inst Monogr. 2019; 2019(53). DOI: 10.1093/jncimonographs/lgz011. View

Chaplin J, Morton R . A prospective, longitudinal study of pain in head and neck cancer patients. Head Neck. 1999; 21(6):531-7. DOI: 10.1002/(sici)1097-0347(199909)21:6<531::aid-hed6>3.0.co;2-m. View

Gotze H, Friedrich M, Taubenheim S, Dietz A, Lordick F, Mehnert A . Depression and anxiety in long-term survivors 5 and 10 years after cancer diagnosis. Support Care Cancer. 2019; 28(1):211-220. DOI: 10.1007/s00520-019-04805-1. View

Paice J . Pain in Cancer Survivors: How to Manage. Curr Treat Options Oncol. 2019; 20(6):48. DOI: 10.1007/s11864-019-0647-0. View

Burton A, Fanciullo G, Beasley R, Fisch M . Chronic pain in the cancer survivor: a new frontier. Pain Med. 2007; 8(2):189-98. DOI: 10.1111/j.1526-4637.2006.00220.x. View

Mirabile A, Airoldi M, Ripamonti C, Bolner A, Murphy B, Russi E . Pain management in head and neck cancer patients undergoing chemo-radiotherapy: Clinical practical recommendations. Crit Rev Oncol Hematol. 2015; 99:100-6. DOI: 10.1016/j.critrevonc.2015.11.010. View

Tesch R, Denardin O, Baptista C, Dias F . Depression levels in chronic orofacial pain patients: a pilot study. J Oral Rehabil. 2004; 31(10):926-32. DOI: 10.1111/j.1365-2842.2004.01379.x. View

Logan H, Bartoshuk L, Fillingim R, Tomar S, Mendenhall W . Metallic taste phantom predicts oral pain among 5-year survivors of head and neck cancer. Pain. 2008; 140(2):323-331. PMC: 2645786. DOI: 10.1016/j.pain.2008.09.004. View

10.

Bossi P, Ghiani M, Argenone A, Depenni R . Is pain part of a systemic syndrome in head and neck cancer?. Support Care Cancer. 2019; 28(2):451-459. DOI: 10.1007/s00520-019-05147-8. View

11.

Treanor C, Donnelly M . Late effects of cancer and cancer treatment--the perspective of the patient. Support Care Cancer. 2015; 24(1):337-346. DOI: 10.1007/s00520-015-2796-4. View

12.

Funk G, Karnell L, Christensen A . Long-term health-related quality of life in survivors of head and neck cancer. Arch Otolaryngol Head Neck Surg. 2012; 138(2):123-33. DOI: 10.1001/archoto.2011.234. View

13.

Epstein J, Miaskowski C . Oral Pain in the Cancer Patient. J Natl Cancer Inst Monogr. 2019; 2019(53). DOI: 10.1093/jncimonographs/lgz003. View

14.

Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2008; 42(2):377-81. PMC: 2700030. DOI: 10.1016/j.jbi.2008.08.010. View

15.

Brandenbarg D, Maass S, Geerse O, Stegmann M, Handberg C, Schroevers M . A systematic review on the prevalence of symptoms of depression, anxiety and distress in long-term cancer survivors: Implications for primary care. Eur J Cancer Care (Engl). 2019; 28(3):e13086. PMC: 9286037. DOI: 10.1111/ecc.13086. View

16.

Sindhu S, Bauman J . Current Concepts in Chemotherapy for Head and Neck Cancer. Oral Maxillofac Surg Clin North Am. 2018; 31(1):145-154. PMC: 6524526. DOI: 10.1016/j.coms.2018.09.003. View

17.

Srivastava P, Kingsley P, Srivastava H, Sachdeva J, Kaur P . Persistent Post-radiotherapy Pain and Locoregional Recurrence in Head and Neck Cancer-Is There a Hidden Link?. Korean J Pain. 2015; 28(2):116-21. PMC: 4387456. DOI: 10.3344/kjp.2015.28.2.116. View

18.

Cluxton C . The Challenge of Cancer Pain Assessment. Ulster Med J. 2019; 88(1):43-46. PMC: 6342038. View

19.

Bossi P, Giusti R, Tarsitano A, Airoldi M, De Sanctis V, Caspiani O . The point of pain in head and neck cancer. Crit Rev Oncol Hematol. 2019; 138:51-59. DOI: 10.1016/j.critrevonc.2019.04.001. View

20.

Oldenmenger W, de Raaf P, de Klerk C, van der Rijt C . Cut points on 0-10 numeric rating scales for symptoms included in the Edmonton Symptom Assessment Scale in cancer patients: a systematic review. J Pain Symptom Manage. 2012; 45(6):1083-93. DOI: 10.1016/j.jpainsymman.2012.06.007. View